Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | DRD4 | P21917 | 3/20 | 0.56 |
| ▸ | DRD3 | P35462 | 3/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8061907 | 1.00 | OPRM1 (0.56) | OPRM1CYP2D6DRD4DRD3DRD2 | |
| SCHEMBL8059835 | 1.00 | OPRM1 (0.56) | OPRM1CYP2D6DRD4DRD3DRD2 | |
| SCHEMBL6560350 | 0.89 | CYP2D6 (0.46) | OPRM1CYP2D6DRD4DRD3DRD2 | |
| SCHEMBL15154320 | 0.85 | CYP2D6 (0.43) | OPRM1CYP2D6DRD4DRD3DRD2 | |
| SCHEMBL9397304 | 0.84 | CYP2D6 (0.44) | OPRM1CYP2D6DRD4DRD3DRD2 | |
| SCHEMBL11600169 | 0.82 | CYP2D6 (0.51) | OPRM1CYP2D6DRD4DRD3DRD2 | |
| Isoaminile SCHEMBL1642905 | 0.80 | EBP (0.52) | OPRM1CYP2D6DRD4DRD3DRD2 | |
| Etaminile SCHEMBL2108910 | 0.79 | GRIN1 (0.50) | OPRM1CYP2D6DRD4DRD3DRD2 | |
| SCHEMBL11728209 | 0.79 | CYP2D6 (0.56) | OPRM1CYP2D6DRD4DRD3DRD2 | |
| SCHEMBL28302049 | 0.79 | CYP2D6 (0.56) | OPRM1CYP2D6DRD4DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385421-A4 | IDENTIFICATION, DIAGNOSIS, AND TREATMENT OF NEUROPATHOLOGIES, NEUROTOXICITIES, TUMORS, AND BRAIN AND SPINAL CORD INJURIES USING MICROELECTRODES WITH MICROVOLTAMMETRY | UNIV CITY (US) | 2007-01-24 | — | — | EP | claimed |
| US-7112319-B2 | Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using microelectrodes with microvoltammetry | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2006-09-26 | — | — | US | claimed |
| EP-1385421-A2 | IDENTIFICATION, DIAGNOSIS, AND TREATMENT OF NEUROPATHOLOGIES, NEUROTOXICITIES, TUMORS, AND BRAIN AND SPINAL CORD INJURIES USING MICROELECTRODES WITH MICROVOLTAMMETRY | The Research Foundation Of the City university of New York (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030032001-A1 | Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using microelectrodes with microvoltammetry | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK, THE | 2003-02-13 | — | — | US | claimed |
| WO-2002082970-A2 | DIAGNOSIS AND TREATMENT OF NEURAL DISEASE AND INJURY USING MICROVOLTAMMETRY | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2002-10-24 | — | — | WO | claimed |
| US-4242274-A | DIPHENYLACETONITRILE, 1-(DIMETHYLAMINO)-2-HALOPROPANE, A BASE, WATER, A SOLVENT, AND A QUATERNARY CATALYST | MALLINCKRODT, INC. (US) | 1980-12-30 | — | — | US | claimed |
| US-4048211-A | Modification of methadone synthesis process step | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | claimed |
| WO-2025123013-A1 | COMPOSITIONS FOR TREATING ADDICTION, DEPENDENCE, WITHDRAWAL, AND/OR OPIOID INDUCED HYPERALGESIA | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250009706-A1 | COMPOSITIONS AND METHODS FOR TREATING OPIOID DEPENDENCE AND WITHDRAWAL | CASE WESTERN RESERVE UNIVERSITY | 2025-01-09 | — | — | US | disclosed |
| WO-2024261775-A1 | A DRUG-ANTAGONIST COMBINATION DOSAGE FORM | PATEL JAYENDRAKUMAR DASHARATHLAL (IN) | 2024-12-26 | — | — | WO | disclosed |
| US-20240390384-A1 | METHODS FOR ACUTE AND LONG-TERM TREATMENT OF OPIOID AND OPIOID-LIKE DRUG ADDICTION | ATAI THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| US-20240217919-A1 | NOVEL METHODS FOR SYNTHESIZING ENANTIOPURE (S)-METHADONE, (R)-METHADONE, RACEMIC (R,S)-METHADONE AND RELATED ANALOGUE SUBSTANCES | MANFREDI PAOLO L (US) | 2024-07-04 | — | — | US | disclosed |
| EP-4373484-A1 | COMPOSITIONS AND METHODS FOR TREATING OPIOID DEPENDENCE AND WITHDRAWAL | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-0187700-B1 | NOVEL AMINOALKYL SUBSTITUTED UREA DERIVATIVES, ACID ADDITION SALTS THEREOF AND ENATIOMERS | H. LUNDBECK A/S (DK) | 1990-04-25 | — | — | EP | disclosed |
| US-4650900-A | ANTITUMOR AGENTS | H. LUNDBECK A/S (DK) | 1987-03-17 | — | — | US | disclosed |
| EP-0187700-A1 | Novel aminoalkyl substituted urea derivatives, acid addition salts thereof and enatiomers | H. LUNDBECK A/S (DK) | 1986-07-16 | — | — | EP | disclosed |
| US-4242274-A | DIPHENYLACETONITRILE, 1-(DIMETHYLAMINO)-2-HALOPROPANE, A BASE, WATER, A SOLVENT, AND A QUATERNARY CATALYST | MALLINCKRODT, INC. (US) | 1980-12-30 | — | — | US | disclosed |
| US-4242274-A | DIPHENYLACETONITRILE, 1-(DIMETHYLAMINO)-2-HALOPROPANE, A BASE, WATER, A SOLVENT, AND A QUATERNARY CATALYST | MALLINCKRODT, INC. (US) | 1980-12-30 | — | — | US | disclosed |
| US-4242274-A | DIPHENYLACETONITRILE, 1-(DIMETHYLAMINO)-2-HALOPROPANE, A BASE, WATER, A SOLVENT, AND A QUATERNARY CATALYST | MALLINCKRODT, INC. (US) | 1980-12-30 | — | — | US | disclosed |
| US-4048211-A | Modification of methadone synthesis process step | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217919-A1 | NOVEL METHODS FOR SYNTHESIZING ENANTIOPURE (S)-METHADONE, (R)-METHADONE, RACEMIC (R,S)-METHADONE AND RELATED ANALOGUE SUBSTANCES | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885CYP2D6 102/4885DRD4 46/4885 |
| US-20250009706-A1 | COMPOSITIONS AND METHODS FOR TREATING OPIOID DEPENDENCE AND WITHDRAWAL | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885CYP2D6 280/4885DRD4 58/4885 |
| US-20240390384-A1 | METHODS FOR ACUTE AND LONG-TERM TREATMENT OF OPIOID AND OPIOID-LIKE DRUG ADDICTION | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885CYP2D6 307/4885DRD4 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.